Q3 2024 Veru Inc Earnings Call Transcript
Key Points
- Veru Inc (VERU) has completed enrollment for its Phase 2b clinical trial for enobosarm, with top-line results expected in January 2025.
- The company has a strong cash position of $29.2 million as of June 30, 2024, which is expected to be sufficient to complete ongoing clinical trials.
- Veru Inc (VERU) reported an increase in net revenues to $4 million for the third quarter, up from $3.3 million in the prior year.
- Operating expenses decreased significantly to $12.4 million from $19.7 million in the previous year, reflecting cost management and strategic focus.
- The company is exploring partnerships for further development and commercialization of its drug candidates, indicating potential future growth opportunities.
- Veru Inc (VERU) reported a net loss of $11 million for the third quarter, although this was an improvement from the previous year's loss.
- The company's US prescription business saw a decline in sales, contributing to a decrease in gross margin from 37% to 34%.
- There is uncertainty regarding the success of the Phase 2b trial for enobosarm, as the results are pending and critical for future development plans.
- The company faces challenges in its US prescription channel due to the bankruptcy of a major customer, impacting revenue streams.
- Veru Inc (VERU) is dependent on securing additional external funding or partnerships to advance its oncology and infectious disease pipeline.
Good morning, ladies and gentlemen, and welcome to Veru Inc.'s investors conference call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Mr. Sam Fisch, Veru Inc.'s, Executive Director, Investor Relations and Corporate Communications. Please go ahead.
Good morning. The statements made on this conference call may be forward-looking statements. Forward-looking statements may include, but are not necessarily limited to, statements of the company's plans, objectives, expectations or intentions regarding its business, operations, regulatory interactions, finances and development and product portfolio. Such forward-looking statements are subject to known and unknown risks and uncertainties, and our actual results may differ significantly from those projected, suggested or included in any forward-looking statements. Risks that may cause actual results or developments to differ materially are contained
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
